William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
William Blair Starts Cameco Corporation (CCJ) at Outperform
-
Fervo Energy Publicly Announces Filing of Registration Statement for Proposed Initial Public Offering
-
Kailera Therapeutics shares surge 62.5% in Nasdaq debut
-
William Blair Assumes Enovis Corp (ENOV) at Outperform
-
William Blair Starts W&T Offshore (WTI) at Outperform
-
William Blair Reiterates Outperform Rating on Netflix (NFLX)
-
Netflix slumps as muted forecasts, Hastings exit deepen growth worries
-
AEVEX Corp. Announces Pricing of Initial Public Offering
-
Kailera Therapeutics prices IPO at $16 per share
-
Kailera Therapeutics Announces Pricing of Initial Public Offering
-
Allogene Therapeutics closes $200.4 million stock offering
-
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
-
Arxis prices IPO at $28 per share, raising $1.13 billion
-
Arcline-Backed Arxis Announces Pricing of its Initial Public Offering
-
Madison Air prices IPO at $27 per share, raising $2.2 billion
-
Madison Air Announces Pricing of Initial Public Offering
-
William Blair walks away from covering Allbirds, Inc. (BIRD), 'This is by any measure a Hail Mary'
-
Allogene prices $175 million stock offering at $2 per share
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Galera and Obsidian merge in $350 million all-stock deal
-
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
-
Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
-
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
-
William Blair Starts Natera (NTRA) at Outperform
-
William Blair stays Outperform on Ocular Therapeutix (OCUL) following Axpaxli data
-
William Blair Reaffirms Outperform on CVRx (CVRX) Following Preliminary Q1 2026 Results
-
Encore files for IPO with SEC, plans NYSE listing
-
Encore Announces Public Filing of Registration Statement with the SEC
-
Suja Life Announces Filing of Registration Statement for Proposed Initial Public Offering
-
Suja Life files for proposed IPO
-
HawkEye 360 files for IPO with NYSE listing planned under HAWK ticker
-
HawkEye 360 Files Registration Statement for Proposed Initial Public Offering
-
HawkEye 360 files for proposed U.S. IPO
-
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
-
William Blair on Neogen (NEOG): waiting for more durable margin improvements
-
William Blair stays Outperform on The Simply Goods Group (SMPL) following disappointing earnings
-
William Blair adds Amazon.com (AMZN) to Conviction List
-
William Blair sees USA Rare Earth Inc (USAR) Carester investment as strategic
-
William Blair on Costco Wholesale (COST): 'no signs of consumer softness here'
-
AEVEX Corp. Announces Launch of Initial Public Offering
-
William Blair Downgrades Hain Celestial (HAIN) to Market Perform
-
Aehr Test Systems sets up $60 million ATM stock sale program
-
William Blair on CarMax (KMX): sales improve but margin risks linger
-
Aehr Test Systems enters $60M equity distribution agreement
-
SunTx Capital Partners' Portfolio Company, Suncrete, and Haymaker Acquisition Corp. 4, Successfully Complete Business Combination
-
William Blair on Meta Platforms Inc. (META): Muse Spark provides 'investor relief' after past criticisms
-
William Blair Reiterates Outperform Rating on Chewy Inc. (CHWY) amid Modern Animal acquisition
-
William Blair Analysts Name Carterra a Winner in Life Science Tools for Enabling AI Drug Discovery at Unprecedented Scale
-
Arxis launches IPO with shares priced between $25-$28

